Table 3.
The chemical structures, status, and known uses of potential drugs for COVID-19 treatment (i.e. drugs appeared in top 100 drugs for all 8 cell lines when comparing their cell-specific predicted gene expression profiles with the patient profile by Spearman’s correlation.
| Drug | Structure | Status | Known Uses |
|---|---|---|---|
| Elbasvir |  |
Approved | Hepatitis C, NS5A inhibitor |
| Pibrentasvir |  |
Approved | Hepatitis C, NS5A inhibitor |
| Velpatasvir |  |
Approved | Hepatitis C, NS5A inhibitor |
| Ruzasvir |  |
Investigational | Hepatitis C, NS5A inhibitor |
| Samatasvir |  |
Investigational | Hepatitis C, NS5A inhibitor |
| Odalasvir |  |
Investigational | Hepatitis C, NS5A inhibitor |
| Coblopasvir |  |
Investigational | Hepatitis C, NS5A inhibitor |
| Baloxavir Marboxil |  |
Approved | Influenza A and B |
| Metocurine |  |
Approved | Muscle relaxant |
| Dactinomycin |  |
Approved | Cancer |
| Laniquidar |  |
Investigational | Cancer, P-glycoprotein inhibitor |
| Tadalafil |  |
Approved | Erectile Dysfunction, PDE5 inhibitors |
| GE-2270A |  |
Experimental | Antibiotic |
| SD146 |  |
Experimental | Binds HIV-1 protease |
| AMG-487 |  |
Experimental | CXCR3 antagonist |